Applied Proteomics raises $22M, hires CEO; ChemoCentryx prices IPO shares at a discount; CoLucid founder dies;

@FierceBiotech: The 25 most influential people in biopharma today. Report | Follow @FierceBiotech

@JohnCFierce: Viehbacher: "2012 has been marked red in my diary for years." More | Follow @JohnCFierce

@FierceMedDev: Merit Medical discloses warning letter regarding Merit Laureate hydrophilic guidewire. Release | Follow @FierceMedDev

> The diagnostics developer Applied Proteomics has raised $22 million, recruited a new CEO and moved to San Diego. Story

> ChemoCentryx has gone public, pricing 4.5 million shares at $10 each. That's well under the $14 to $16 range the company shot for, offering another example of the difficulties drug developers have with IPOs these days. Story

> James White, the co-founder of CoLucid Pharmaceuticals, has died. White and Art Pappas started the company back in 2005 to develop lasmiditan for acute migraines. Release

@FiercePharma: Can you imagine what Sanofi would look like now if it hadn't bought Genzyme? | Follow @FiercePharma

> Don't look for Lundbeck earnings growth until 2015. Story

> GSK moves European cash to U.K. nightly 'just in case.' Article

> Sanofi CEO: Look out below, profits are falling. Piece

Medical Device News

> Zimmer, ISTO start Phase III study of DeNovo tissue graft. Item

> Siemens teams up with ViiV, Tocagen on companion Dx. Article

> FDA advocates for device 'bar code' in face of OMB delay. More

> Velomedix scores $10.2M in Series B, taps new CEO. News

> Merit, PhotoMedex recipients of FDA warning letters. Piece

Biomarkers News

> Gene signature predicts cancer outcomes. More

> Heart attack? No, it's just a spinning class. Story

> Alzheimer's marker is seen in middle age. Article

> Personalized medicine grows in China with Chinese/Canadian collaboration. News

> Urine biomarker spots aggressive prostate cancer. More

Drug Delivery News

> DexCom, Tandem Diabetes pursue combined CGM/insulin pump. Story

> OptiNose testing nose-to-brain delivery tech with migraine drug. More

> Report: China ramping up for global drug delivery tech battle. Article

> GW's cannabis-based mouth spray gains Austrian OK for MS spasms. News

And Finally... Is exercise the best drug? Penn State investigators say there's a clear connection between exercise and improved levels of enthusiasm and excitement. Release

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.